How the practice of allergy shows the promise and challenge of personalized medicine

Molecular Genetics and Metabolism

Volumn 104, Issue 1-2, 2011, Pages 3-6

  McGhee, Sean A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; Cost effectiveness; Patient safety; Personalized medicine

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; CORTICOSTEROID; WARFARIN; ZILEUTON;

ALLERGIC ASTHMA; ALLERGY; ANAPHYLAXIS; ASTHMA; COST EFFECTIVENESS ANALYSIS; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; GENOME; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MEDICAL INFORMATION; NOTE; PATIENT CARE; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLERGENS; GENOME, HUMAN; GOVERNMENT REGULATION; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; PATIENT SAFETY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052524579     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.07.017     Document Type: Note

References (40)

1. Schwarz U.I., Ritchie M.D., Bradford Y., Li C., Dudek S.M., Frye-Anderson A., et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 2008, 358(10):999-1008. [Research Support, N.I.H., Extramural].
2. Yan L., Beckman R. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques 2005 Oct, 39(Suppl. 10):S565-S568. Review.
3. Duffy M.J., Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin. Chem. 2008, 54(11):1770-1779. [Research Support, Non-U.S. Gov't Review].
4. Collins I., Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2006 Dec, 2(12):689-700. [Research Support, Non-U.S. Gov't Review].
5. Elkin E.B., Marshall D.A., Kulin N.A., Ferrusi I.L., Hassett M.J., Ladabaum U., et al. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011, [Epub ahead of print].
6. Conti R., Veenstra D.L., Armstrong K., Lesko L.J., Grosse S.D. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med. Decis. Making. 2010, 30(3):328-340.
7. Noon L. Prophylactic innoculation against hay fever. Lancet 1911, 1:1572-1573.
8. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., et al. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol. 2011, 127(Suppl. 1):S1-S55. [Practice Guideline].
9. Allergenics. U.S. Food and Drug Administration [cited 2011 June 16, 2011]; Available from:. http://www.fda.gov/BiologicsBloodVaccines/Allergenics/default.htm.
10. James J.M., Corbett M. The American Board of Allergy and Immunology maintenance of certification program. Ann. Allergy. Asthma Immunol. 2011, 106(6):549. [Letter].
11. James J.M., Corbett M. The American Board of Allergy and Immunology maintenance of certification program: "to do or not to do? That is the question.". Ann. Allergy Asthma Immunol. 2010, 105(6):485-488.
12. Dubravec M.S. The burdensome maintenance of certification process. Ann. Allergy Asthma Immunol. 2011, 106(4):351. [Letter].
13. Bernstein D.I., Epstein T. Systemic reactions to subcutaneous allergen immunotherapy. Immunol. Allergy Clin. North Am. 2011, 31(2):241-249. [viii-ix].
14. Lopez-Picazo J.J., Ruiz J.C., Sanchez J.F., Ariza A., Aguilera B., Lazaro D., et al. Prevalence and typology of potential drug interactions occurring in primary care patients. Eur. J. Gen. Pract. 2010, 16(2):92-99.
15. Hepner M.J., Ownby D.R., Anderson J.A., Rowe M.S., Sears-Ewald D., Brown E.B. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J. Allergy Clin. Immunol. 1990, 86(3 Pt 1):407-411.
16. Chung L.P., Waterer G., Thompson P.J. Pharmacogenetics of beta2 adrenergic receptor gene polymorphisms, long-acting beta-agonists and asthma. Clin. Exp. Allergy 2011, 41(3):312-326. [Review].
17. Lemanske R.F., Mauger D.T., Sorkness C.A., Jackson D.J., Boehmer S.J., Martinez F.D., et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med. 2010, 362(11):975-985. [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural].
18. Peters S.P., Kunselman S.J., Icitovic N., Moore W.C., Pascual R., Ameredes B.T., et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 2010, 363(18):1715-1726. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural].
19. Martin R.J., Szefler S.J., King T.S., Kraft M., Boushey H.A., Chinchilli V.M., et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J. Allergy Clin. Immunol. 2007, 119(1):73-80. [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural].
20. Kobilka B.K., Frielle T., Dohlman H.G., Bolanowski M.A., Dixon R.A., Keller P., et al. Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions. J. Biol. Chem. 1987, 262(15):7321-7327. [Comparative Study].
21. Hawkins G.A., Tantisira K., Meyers D.A., Ampleford E.J., Moore W.C., Klanderman B., et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am. J. Respir. Crit. Care Med. 2006, 174(10):1101-1109. [Research Support, N.I.H., Extramural].
22. Green S.A., Cole G., Jacinto M., Innis M., Liggett S.B. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 1993, 268(31):23116-23121. [Research Support, U.S. Gov't, P.H.S.].
23. Green S.A., Turki J., Hall I.P., Liggett S.B. Implications of genetic variability of human beta 2-adrenergic receptor structure. Pulm. Pharmacol. 1995, 8(1):1-10. [Research Support, U.S. Gov't, P.H.S. Review].
24. Green S.A., Turki J., Innis M., Liggett S.B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994, 33(32):9414-9419. [Research Support, U.S. Gov't, P.H.S.].
25. Grainger J., Woodman K., Pearce N., Crane J., Burgess C., Keane A., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991, 46(2):105-111. [Research Support, Non-U.S. Gov't].
26. Pearce N. The use of beta agonists and the risk of death and near death from asthma. J. Clin. Epidemiol. 2009, 62(6):582-587. [Historical Article Research Support, Non-U.S. Gov't].
27. Pearce N., Burgess C., Crane J., Beasley R. Fenoterol, asthma deaths, and asthma severity. Chest 1997, 112(4):1148-1150. [Comment Letter].
28. Basu K., Palmer C.N., Tavendale R., Lipworth B.J., Mukhopadhyay S. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J. Allergy Clin. Immunol. 2009, 124(6):1188-94. [Research Support, Non-U.S. Gov't].
29. Wechsler M.E., Kunselman S.J., Chinchilli V.M., Bleecker E., Boushey H.A., Calhoun W.J., et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009, 374(9703):1754-1764. [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural].
30. de Alarcon A., Steinke J.W., Caughey R., Barekzi E., Hise K., Gross C.W., et al. Expression of leukotriene C4 synthase and plasminogen activator inhibitor 1 gene promoter polymorphisms in sinusitis. Am. J. Rhinol. 2006, 20(5):545-549. [Comparative Study].
31. Stevenson D.D., Zuraw B.L. Pathogenesis of aspirin-exacerbated respiratory disease. Clin. Rev. Allergy Immunol. 2003, 24(2):169-188. [Review].
32. Wang X.S., Wu A.Y., Leung P.S., Lau H.Y. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease. Allergy 2007, 62(6):620-627. [Research Support, Non-U.S. Gov't].
33. Berges-Gimeno M.P., Simon R.A., Stevenson D.D. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin. Exp. Allergy 2002, 32(10):1491-1496. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
34. Berges-Gimeno M.P., Simon R.A., Stevenson D.D. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 2003, 111(1):180-186. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
35. Rizk H. Role of aspirin desensitization in the management of chronic rhinosinusitis. Curr. Opin. Otolaryngol. Head Neck. Surg. 2011, 19(3):210-217.
36. Stevenson D.D. Aspirin desensitization in patients with AERD. Clin. Rev. Allergy Immunol. 2003, 24(2):159-168. [Review].
37. Williams A.N., Woessner K.M. The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. Curr. Allergy Asthma Rep. 2008, 8(3):245-252. [Review].
38. Collins L.J., Penny D. The RNA infrastructure: dark matter of the eukaryotic cell?. Trends Genet. 2009, 25(3):120-128. [Research Support, Non-U.S. Gov't Review].
39. Weinstein M.C., Skinner J.A. Comparative effectiveness and health care spending-implications for reform. N. Engl. J. Med. 2010, 362(5):460-465. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
40. Garber A.M., Tunis S.R. Does comparative-effectiveness research threaten personalized medicine?. N. Engl. J. Med. 2009, 360(19):1925-1927.